TIDMFARN
RNS Number : 4144S
Faron Pharmaceuticals Oy
06 November 2023
Faron Pharmaceuticals Ltd.
("Faron or Company")
The Board of Directors of Faron Has Resolved on a Warrant
Program and an Issuance of 319,944 Warrants to IPF Partners
Company announcement, February 28, 2022 - 07:45 PM (EET) / 05:45
PM (GMT) / 12:45 PM (EST)
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM:
FARN, First North: FARON), a clinical stage biopharmaceutical
company focused on building the future of immunotherapy by
harnessing the power of the immune system to tackle cancer and
inflammation, announced today, February 28, 2022, that it had
entered into a secured debt agreement (the "Funding Agreement")
with IPF Partners ("IPF"). As part of the arrangement relating to
the Funding Agreement, Faron has committed to granting IPF special
rights entitling them to subscribe for ordinary shares of the
Company against payment ("Warrants").
In accordance with the Funding Agreement, the Board of Directors
of the Company has on Monday February 28 2022, based on an
authorization granted to the Board by shareholders at the Company's
Annual General Meeting held on April 23, 2021, resolved upon a
warrant program directed to IPF. Pursuant to the warrant program,
the Warrants are issued without consideration. The Warrants are
issued as a part of Funding Agreement and therefore, from the
Company's point of view, there is a weighty financial reason for
the program and the issuance of Warrants thereunder.
Pursuant to the warrant program, the Warrants are issued at the
date of each drawdown under the Funding Agreement. The maximum
total number of warrants to be granted under the current warrant
program agreed on Monday February 28, 2022 is 600,000, under the
authorization granted to the Board by shareholders at the Company's
Annual General Meeting held on April 23, 2021. Each warrant
entitles its holder to subscribe for one new share in the Company.
The subscription price per share on the basis of the Warrants will
equal the 30-day volume-weighted average price of an ordinary share
of Faron on the Nasdaq Helsinki First North exchange immediately
preceding the drawdown date of the respective tranche. The Warrants
may be exercised for a period of seven years following the drawdown
of each tranche under the Funding Agreement, except for the first
drawdown, for which the subscription period will commence on March
25, 2022 and end on the date falling seven years after such date.
The terms and conditions of the Warrants will be available on the
Company's website at: https://www.faron.com/investors/aim-rule-26
.
As announced on Monday February 28, 2022 , the Company has
pursuant to the warrant program resolved to issue 319,944 Warrants
to IPF in relation to the first tranche utilized on Monday,
February 28, 2022. The subscription price per share with respect to
Warrants issued in respect of the drawdown of the first tranche is,
in accordance with the above, EUR 3.126 per share (subject to
adjustment in accordance with the terms and conditions of the
Warrants).
For more information please contact:
Media / Investor Contact
Faron Pharmaceuticals
Eric Van Zanten
Head of Communications
eric.vanzanten@faron.com
Investor.relations@faron.com
Phone: +1 (610) 529-6219
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs caused by dysfunction of
our immune system. The Company currently has a pipeline based on
the receptors involved in regulation of immune response in
oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanized antibody, is its investigative
precision immunotherapy with the potential to provide permanent
immune stimulation for difficult-to-treat cancers through targeting
myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with untreatable solid tumors,
bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune
checkpoint molecules. Traumakine is an investigational intravenous
(IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or
hyperinflammatory conditions. Traumakine is currently being
evaluated in global trials as a potential treatment for
hospitalized patients with COVID-19 and with the 59th Medical Wing
of the US Air Force and the US Department of Defense for the
prevention of multiple organ dysfunction syndrome (MODS) after
ischemia-reperfusion injury caused by a major trauma. Faron is
based in Turku, Finland. Further information is available at
www.faron.com .
Forward Looking Statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identified by their use of terms and phrases such as "believe",
"could", "should", "expect", "hope", "seek", "envisage",
"estimate", "intend", "may", "plan", "potentially", "will" or the
negative of those, variations or comparable expressions, including
references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other
expenditures (including the amount, nature and sources of funding
thereof), competitive advantages, business prospects and
opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on
information currently available to the Directors.
A number of factors could cause actual results to differ
materially from the results and expectations discussed in the
forward-looking statements, many of which are beyond the control of
the Company. In particular, the early data from initial patients in
the MATINS trial may not be replicated in larger patient numbers
and the outcome of clinical trials may not be favourable or
clinical trials over and above those currently planned may be
required before the Company is able to apply for marketing approval
for a product. In addition, other factors which could cause actual
results to differ materially include the ability of the Company to
successfully licence its programmes within the anticipated
timeframe or at all, risks associated with vulnerability to general
economic and business conditions, competition, environmental and
other regulatory changes, actions by governmental authorities, the
availability of capital markets or other sources of funding,
reliance on key personnel, uninsured and underinsured losses and
other factors. Although any forward-looking statements contained in
this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward looking
statements. Accordingly, readers are cautioned not to place undue
reliance on forward looking statements. Subject to any continuing
obligations under applicable law or any relevant AIM Rule
requirements, in providing this information the Company does not
undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events,
conditions or circumstances on which any such statement is
based.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBABLTMTJMBJJ
(END) Dow Jones Newswires
November 06, 2023 02:00 ET (07:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024